Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors
Name
jocmr-11-609.pdf
Description
Published version
Size
1005.12 KB
Format
Adobe PDF
Checksum (MD5)
7ec7b588428262ea6b7ed1e0e316ef0f
Author(s)
Tonegawa, Susumu
Date Issued
2019
Journal
Journal of clinical medicine and research
Publisher
Elmer Press, Inc.
Citation
Hayashi,Takuma et al. “Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors.” Journal of clinical medicine and research 11 (2019): 609-613 © 2019 The Author(s)
Version
Final published version
Abstract
The use of anti-human signal molecules monoclonal antibod-ies (mAbs) for malignant tumors therapy has achieved consid-erable success in recent years. Antibody drug conjugates are powerful new clinical treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also re-cently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of ma-lignant tumor serology, protein-engineering techniques, mech-anisms of action and resistance, and the interplay between the immune system and tumorigenesis. This review outlines the fundamental strategies, which are required to establish anti-body therapies for patients with mesenchymal tumors through iterative approaches to target and antibody selection, extend-ing from preclinical studies to human trials.
MIT Department
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution NonCommercial License 4.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.14740/jocmr3886
